Phase 3 N=27 Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon
Type 1 Diabetes · Dawn Phenomenon
Primary: Blood Glucose Area Under the Curve (AUC) — 1673.33; 1395 mg*10hr/dL — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=293 GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
Renal Failure · Hemodialysis
Primary: Target Lesion Primary Patency at 6 Months — 52.9; 35.5 Percentage of Subjects
Phase 3 N=106 Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Primary: Part A: Number of Participants With Adverse Events (AEs) — 8; 4; 1; 3 participants
Phase 3 N=849 Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005
Phase 3 N=361 A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks — -1.44; -0.90 percentage of HbA1c — p=<0.001
Phase 3 N=112 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea
Rosacea
Primary: Composite Success Assessment (CEA) and Patient Self Assessment(PSA). — 32; 48; 33; 46 participants
Phase 3 N=844 Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
Opioid-Induced Constipation (OIC)
Primary: Incidence of Patients Experiencing at Least One Adverse Event (AE) — 437; 195 Participants
Phase 3 N=392 Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
Asthma
Primary: FEV1 peak0-3 Change From Baseline — 0.438; 0.550; 0.528 litres — p=0.0457
Phase 3 N=80 Post Traumatic Stress Disorder (PTSD) Hyperarousal Symptoms Treated With Physiological Stress Management
Stress Disorders, Post-Traumatic
Primary: Change Scores for Criteria D Items on the CAPS Structured Clinical Interview — -1.20; -6.27 units on a scale — p=.27
Phase 3 N=71 A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs) — 14.1; 2.8; 4.2 percentage of participants
Phase 3 N=353 Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes
Primary: Change From Baseline to Week 24 in HbA1c — -0.82; -0.42 percentage of hemoglobin — p=<0.0001
Phase 3 N=260 Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
Chronic Kidney Disease
Primary: Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2) — 4.03; 42.55; 2.76; 49.84 Percent Change of LDL-cholesterol
Phase 3 N=351 Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18…
Phase 3 N=677 Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up
Diabetes Type 2
Primary: Change From Baseline in HbA1c to Week 52 — -0.59; -0.71 percent
Phase 3 N=84 Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
Non-24-Hour Sleep-Wake Disorder
Primary: Proportion of Patients Entrained as Assessed by Urinary aMT6 — 20; 2.6 percentage of patients